20 Aug 2025
National Institute for Health & Care Excellence
Key changes include: Earlier use of newer medicines – SGLT-2 inhibitors (such as canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin) are now recommended as first-line options alongside met
…
){kind=logo}
){kind=logo}
)